TrialDiff
TrialDiff turns ClinicalTrials.gov amendment history into citeable evidence records: exact changed paths, source hashes, deterministic rules, timing context, and explicit claims-supported / claims-not-supported boundaries.
v0.1.3 · Corpus snapshot through 2026-05-22 · rule set fc87f4f0a74b
| Trial | Sponsor | Patches | Critical triage | High triage | Critical-triage density |
|---|---|---|---|---|---|
| NCT00165256 Wide Excision Alone as Treatment for Ductal Carcinoma in Situ of The Breast | Dana-Farber Cancer Institute | 17 | 3 | 9 | 17.65%
critical-triage events / patches |
| NCT03094169 AVID100 in Advanced Epithelial Carcinomas | Formation Biologics | 13 | 2 | 6 | 15.38%
critical-triage events / patches |
| NCT02154529 Study of the Combination of KD019 and Trastuzumab in Subjects With HER2-Positive Metastatic Breast Cancer | Kadmon Corporation, LLC | 24 | 3 | 7 | 12.50%
critical-triage events / patches |
| NCT03393845 Study of Pembrolizumab Plus Fulvestrant in Hormone Receptor Positive, HER-2 Negative Advanced/Metastatic Breast Cancer Patients | Nancy Chan, MD | 17 | 2 | 6 | 11.76%
critical-triage events / patches |
| NCT01147016 Targeted T Cells After Neoadjuvant Chemotherapy in Treating Women With Stage II or III Breast Cancer Undergoing Surgery | Barbara Ann Karmanos Cancer Institute | 19 | 2 | 9 | 10.53%
critical-triage events / patches |
| NCT02229084 Vaccination of High Risk Breast Cancer Patients | University of Arkansas | 19 | 2 | 3 | 10.53%
critical-triage events / patches |
| NCT00879086 A Study Comparing Eribulin Mesylate and Ixabepilone in Causing or Exacerbating Neuropathy in Participants With Advanced Breast Cancer | Eisai Inc. | 10 | 1 | 5 | 10.00%
critical-triage events / patches |
| NCT03283384 Tailoring NEOadjuvant Therapy in Hormone Receptor Positive, HER2 Negative, Luminal Breast Cancer. | Borstkanker Onderzoek Groep | 10 | 1 | 3 | 10.00%
critical-triage events / patches |
| NCT04756765 Talazoparib Monotherapy in PALB2 Mutation Associated Advanced Breast Cancer | Stanford University | 10 | 1 | 1 | 10.00%
critical-triage events / patches |
| NCT00629616 Efficacy of Anastrozole and Fulvestrant in Patients With ER Positive, HER2 Negative, Operable Breast Cancer | UNICANCER | 11 | 1 | 5 | 9.09%
critical-triage events / patches |
| NCT05593094 A Phase 1 Trial of ZN-A-1041 Enteric Capsules or Combination in Participants With Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Advanced Solid Tumors | Hoffmann-La Roche | 11 | 1 | 4 | 9.09%
critical-triage events / patches |
| NCT04278144 A First-in-human Study Using BDC-1001 as a Single Agent and in Combination With Nivolumab in Advanced HER2-Expressing Solid Tumors | Bolt Biotherapeutics, Inc. | 34 | 3 | 5 | 8.82%
critical-triage events / patches |
| NCT03414684 Carboplatin +/- Nivolumab in Metastatic Triple Negative Breast Cancer | Dana-Farber Cancer Institute | 23 | 2 | 3 | 8.70%
critical-triage events / patches |
| NCT03735680 A Study to Evaluate ONM-100, an Intraoperative Fluorescence Imaging Agent for the Detection of Cancer | OncoNano Medicine, Inc. | 12 | 1 | 8 | 8.33%
critical-triage events / patches |
| NCT03025035 Pembrolizumab in Combination With Olaparib in Advanced BRCA-mutated or HDR-defect Breast Cancer | Yuan Yuan | 25 | 2 | 10 | 8.00%
critical-triage events / patches |
| NCT03584009 A Phase II Study Comparing The Efficacy Of Venetoclax + Fulvestrant Vs. Fulvestrant In Women With Estrogen Receptor-Positive, Her2-Negative Locally Advanced Or Metastatic Breast Cancer Who Experienced Disease Recurrence Or Progression During Or After CDK4/6 Inhibitor Therapy | Hoffmann-La Roche | 25 | 2 | 4 | 8.00%
critical-triage events / patches |
| NCT01142401 Fulvestrant With or Without Bortezomib in Patients With Inoperable Locally Advanced or Metastatic Estrogen Receptor Positive Breast Cancer | National Cancer Institute (NCI) | 53 | 4 | 4 | 7.55%
critical-triage events / patches |
| NCT02297412 Minocycline Hydrochloride in Reducing Chemotherapy-Induced Peripheral Neuropathy and Acute Pain in Patients With Breast Cancer Undergoing Treatment With Paclitaxel | Academic and Community Cancer Research United | 14 | 1 | 2 | 7.14%
critical-triage events / patches |
| NCT01471106 Phase II Short-term Adjuvant Therapy and Biomarker Studies With Targeted Agents in Women With Estrogen Receptor Negative Breast Cancer | M.D. Anderson Cancer Center | 29 | 2 | 10 | 6.90%
critical-triage events / patches |
| NCT02576431 A Study to Test the Effect of the Drug Larotrectinib in Adults and Children With NTRK-fusion Positive Solid Tumors | Bayer | 96 | 6 | 8 | 6.25%
critical-triage events / patches |
| NCT03734029 Trastuzumab Deruxtecan (DS-8201a) Versus Investigator's Choice for HER2-low Breast Cancer That Has Spread or Cannot be Surgically Removed [DESTINY-Breast04] | Daiichi Sankyo | 32 | 2 | 5 | 6.25%
critical-triage events / patches |
| NCT01033032 Trial of Amrubicin as Treatment for Patients With HER2-Negative Metastatic Breast Cancer | SCRI Development Innovations, LLC | 17 | 1 | 5 | 5.88%
critical-triage events / patches |
| NCT01818063 Carboplatin and Combination Chemotherapy With or Without Veliparib in Treating Patients With Stage IIB-IIIC Breast Cancer | Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University | 19 | 1 | 3 | 5.26%
critical-triage events / patches |
| NCT04224272 A Study of ZW25 (Zanidatamab) With Palbociclib Plus Fulvestrant in Patients With HER2+/HR+ Advanced Breast Cancer | Jazz Pharmaceuticals | 20 | 1 | 2 | 5.00%
critical-triage events / patches |
| NCT04482309 A Phase 2 Study of T-DXd in Patients With Selected HER2 Expressing Tumors | AstraZeneca | 51 | 2 | 4 | 3.92%
critical-triage events / patches |